Simvastatin increases the antineoplastic actions of paclitaxel carried in lipid nanoemulsions in melanoma-bearing mice

• Published in: International journal of nanomedicine 2016-01, Vol.11 (Issue 1), p.885-904
• Main Authors: Kretzer, Iara F, Maria, Durvanei A, Guido, Maria C, Contente, Thaís C, Maranhão, Raul C
• Format: Article
• Language: English
• Subjects: Animals; Antilipemic agents; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Apoptosis - drug effects; Blood cholesterol; Blotting, Western; Cancer therapies; Cancer treatment; Cell growth; Cell Proliferation - drug effects; Cholesterol, LDL - metabolism; drug delivery; Drug Synergism; Female; Immunoenzyme Techniques; Injections, Intraperitoneal; Kinases; Laboratories; lipid nanoparticles; Lipids; Lipids - chemistry; Low density lipoproteins; Melanoma; Melanoma, Experimental - drug therapy; Melanoma, Experimental - metabolism; Melanoma, Experimental - pathology; Mice; Mice, Inbred C57BL; Original Research; Paclitaxel - administration & dosage; Receptors, LDL - metabolism; Simvastatin; Simvastatin - administration & dosage; statins; Tumor Cells, Cultured
• ISSN: 1178-2013; 1176-9114; 1178-2013
• DOI: 10.2147/IJN.S88546

Lipid nanoemulsions (LDEs) that bind to low-density lipoprotein (LDL) receptors used as carriers of paclitaxel (PTX) can decrease toxicity and increase PTX antitumoral action. The administration of simvastatin (Simva), which lowers LDL-cholesterol, was tested as an adjuvant to commercial PTX and to PTX associated with LDE (LDE-PTX). B16F10 melanoma-bearing mice were treated with saline solution or LDE (controls), Simva, PTX, PTX and Simva, LDE-PTX, and LDE-PTX and Simva: PTX dose 17.5 μmol/kg (three intraperitoneal injections, 3 alternate days): Simva 50 mg/kg/day by gavage, 9 consecutive days. Compared with saline controls, 95% tumor-growth inhibition was achieved by LDE-PTX and Simva, 61% by LDE-PTX, 44% by PTX and Simva, and 43% by PTX. Simva alone had no effect. Metastasis developed in only 37% of the LDE-PTX and Simva, 60% in LDE-PTX, and 90% in PTX and Simva groups. Survival rates were higher in LDE-PTX and Simva and in LDE-PTX groups. The LDE-PTX and Simva group presented tumors with reduced cellular density and increased collagen fibers I and III. Tumors from all groups showed reduction in immunohistochemical expression of ICAM, MCP-1, and MMP-9; LDE-PTX and Simva presented the lowest MMP-9 expression. Expression of p21 was increased in the Simva, LDE-PTX, and LDE-PTX and Simva groups. In the Simva and LDE-PTX and Simva groups, expression of cyclin D1, a proliferation and survival promoter of tumor cells, was decreased. Therapy with LDE-PTX and Simva showed negligible toxicity compared with PTX and Simva, which resulted in weight loss and myelosuppression. Simva increased the antitumor activity of PTX carried in LDE but not of PTX commercial presentation, possibly because statins increase the expression of LDL receptors that internalize LDE-PTX.